by Paul Alan Levy Many groups at Public Citizen issue hard-hitting reports, but we are scrupulous about reviewing reports about particular companies and individuals to ensure their accuracy, not to speak of avoiding the prospect of libel litigation. This was certainly true with respect to letters to the FDA back in July, asking why it […]
